Medifast (NYSE:MED) Issues Q3 2026 Earnings Guidance

Medifast (NYSE:MED) issued an update on its third quarter 2026 earnings guidance on Monday. The company provided earnings per share guidance of -0.650–0.150 for the period, compared to the consensus estimate of -0.620. The company issued revenue guidance of $60.0 million-$80.0 million, compared to the consensus revenue estimate of $68.0 million. Medifast also updated its FY 2026 guidance to -1.750–0.250 EPS.

Analyst Ratings Changes

MED has been the topic of a number of recent analyst reports. Zacks Research upgraded Medifast from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Weiss Ratings downgraded shares of Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $12.00.

Medifast Price Performance

Shares of MED traded down $0.10 during trading hours on Monday, hitting $9.72. The company’s stock had a trading volume of 230,646 shares, compared to its average volume of 234,457. The company has a market cap of $108.14 million, a price-to-earnings ratio of -5.31 and a beta of 0.65. The business has a 50 day simple moving average of $11.11 and a two-hundred day simple moving average of $11.05. Medifast has a 52-week low of $9.22 and a 52-week high of $15.11.

Medifast (NYSE:MED) last announced its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. The company had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $72.70 million. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Research analysts predict that Medifast will post -1.97 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Scott Schlackman acquired 2,500 shares of Medifast stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $12.53 per share, with a total value of $31,325.00. Following the completion of the purchase, the director owned 30,549 shares in the company, valued at approximately $382,778.97. The trade was a 8.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 3.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medifast

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Medifast in the third quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management bought a new stake in shares of Medifast during the 4th quarter worth $47,000. State of Wyoming bought a new position in Medifast in the fourth quarter valued at $59,000. Finally, Strs Ohio purchased a new stake in Medifast during the first quarter valued at about $78,000. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.